TITLE

Serous Cystadenocarcinoma of the Pancreas: Clinical Features and Management of a Rare Tumor

AUTHOR(S)
Van Dyke, Timothy J.; Johlin, Frederick C.; Bellizzi, andrew M.; Howe, James R.
PUB. DATE
April 2016
SOURCE
Digestive Surgery;Apr2016, Vol. 33 Issue 3, p240
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background/Aims: The vast majority of serous cystic neoplasms of the pancreas are benign, and small, asymptomatic lesions, which are generally managed with observation. However, some of these tumors may attain a large size and occasionally metastasize. Methods: In this study, we present a 78-year-old man with serous cystadenocarcinoma of the pancreas with liver metastases treated by distal pancreatectomy and liver ablation, who went on to develop new liver metastases 5 years after the initial operation. We perform a literature review to determine the number of these malignant neoplasms previously reported and to identify features associated with malignant lesions. Results: Literature reveals that metastatic serous cystadenocarcinomas of the pancreas are rare tumors, occurring in less than 3% of cases of serous cystic neoplasms. All malignant cases reported have been in tumors >4 cm in size. Conclusions: Serous cystic neoplasms of the pancreas >4 cm have malignant potential and therefore should be considered for surgical management.
ACCESSION #
114941735

 

Related Articles

  • Onconova Presents Positive Data on ESTYBON(r) (rigosertib, ON 01910.Na), a Novel Phase III Anti-Cancer Agent, at ASCO 2011.  // Biomedical Market Newsletter;6/9/2011, p504 

    The article focuses on the result of Phase I study on the clinical development of ESTYBON ® which was presented by Oncova Therapeutics Inc. at the 2011 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on June 3-7. It says that ESTYBON combined with rigosertib,...

  • Radiation Therapy Deviations in Trial of Locally Advanced Pancreatic Cancer [corrected]. Jani, Ashish; Horowitz, David P. // JAMA: Journal of the American Medical Association;10/4/2016, Vol. 316 Issue 13, p1409 

    A letter to the editor is presented in response to the article "Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 Randomized Clinical Trial" in the May 2016 issue.

  • Radiation Therapy Deviations in Trial of Locally Advanced Prostate Cancer-Reply. Huguet, Florence; Goldstein, David; Hammel, Pascal // JAMA: Journal of the American Medical Association;10/4/2016, Vol. 316 Issue 13, p1409 

    A response from the authors of the article "Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 Randomized Clinical Trial" in the May 3, 2016 issue is presented.

  • Anticancer drugs: Switch control. Novak, Kristine // Nature Reviews Cancer;Jun2003, Vol. 3 Issue 6, p391 

    Focuses on a study to test the effects of various therapeutic approaches on distinct stages of tumor development published in the May issue of 'The Journal of Clinical Investigation.' Role of vascular endothelial growth factor receptor inhibitor in preventing the growth of premalignant tumors;...

  • The Success of Endoscopic Third Ventriculostomy in Children: Analysis of Prognostic Factors. Furlanetti, Luciano Lopes; Santos, Marcelo Volpon; de Oliveira, Ricardo Santos // Pediatric Neurosurgery;Sep2013, Vol. 48 Issue 6, p352 

    Objective: The treatment of hydrocephalus in children with endoscopic third ventriculostomy (ETV) has particular features and is associated with different success rates (SR). The aim of this study was to identify putative factors that could influence the outcome of ETV in children. Methods:...

  • Pancreatic adenocarcinoma: the impact of preneoplastic lesion pattern on survival. Flattet, Yves; Andrejevic-Blant, Snezana; Yamaguchi, Takamune; Halkic, Nermin // BioScience Trends;Dec2015, Vol. 9 Issue 6, p402 

    Pancreatic adenocarcinoma is associated with a very poor prognosis, characterized with a 5-year survival rate of only 5%. Surgery is the only curative treatment for selected patients. Nevertheless, recurrence is very frequent. Identifying prognostic factors is thus warranted. Like numerous other...

  • Multidisciplinary diagnostic and therapeutic approaches to pancreatic cystic lesions. Clores, Michael J.; Thosani, Amar; Buscaglia, Jonathan M. // Journal of Multidisciplinary Healthcare;2014, Vol. 7, p81 

    Pancreatic cystic lesions are commonly encountered today with the routine use of cross-sectional imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI). The majority of patients discovered to have a pancreatic cyst are completely asymptomatic; yet the presence...

  • Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine-induced killer cell therapy in hepatobiliary and pancreatic cancer. LIHONG ZHANG; WEI ZHU; JIALI LI; XUEJING YANG; YANJIE REN; JINGXIU NIU; YAN PANG // Molecular & Clinical Oncology;Jan2016, Vol. 4 Issue 1, p129 

    The aim of this study was to determine the therapeutic effects of adoptive immunotherapy following dendritic cell (DC) vaccine and cytokine-induced killer (CIK) cell therapy and evaluate its cytotoxicity, survival benefits and quality of life (QOL) changes in patients with hepatobiliary and...

  • 21-Year-Old Male Trauma Patient With Skin and Liver Lesions, Hepatitis, and Coagulopathy.  // Clinical Infectious Diseases;Feb2013, Vol. 56 Issue 4, p559 

    A photo quiz is presented which ask the readers to diagnose the disease in a 21-year old patient who was presented with clinical conditions of skin and liver lesions, hepatitis, and coagulopathy.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics